First published online: 26 Nov 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2017;6(1):61-64.
doi: 10.15171/jrip.2017.11
PMID: 28487874
PMCID: PMC5414521
Scopus id: 85040675359
  Abstract View: 1787
  PDF Download: 907

Original Article

Administration of pentoxifylline to improve anemia of hemodialysis patients

Heshmatolah Shahbazian 1, Ali Ghorbani 1, Azita Zafar-Mohtashami 2 * , Abdolreza Balali 3, Armaghan AleAli 1, Gholam Reza Lashkarara 4

1 Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Internal Medicine, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khoramabad, Iran
3 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Lorestan University of Medical Sciences, Khoramabad, Iran
*Corresponding author: Azita Zafar-Mohtashami, Email: nazbani@yahoo.com

Article

Introduction: One of the most important causes of erythropoietin-resistant anemia in end-stage renal disease (ESRD) patients is increased levels of inflammatory cytokines.Objectives: In this study pentoxifylline, an anti-inflammatory and anti-cytokine drug, with no significant side effects was used to manage anemia in ESRD patients.

Patients and Methods: Thirty-nine ESRD patients with erythropoietin-resistant anemia were assigned to two groups, the treatment and the control groups. In treatment group, 19 patients received erythropoietin, venofer and pentoxifylline for 6 months.

Patients in control group received erythropoietin and venofer. Hemoglobin (Hb), hematocrit (Hct), albumin and quantitative C-reactive protein (CRP) were measured at the beginning of the study, monthly and at the end of the study.

Results: Hb and Hct were significantly increased in the treatment group (9.33±1.25 g/dL and 28.08±3.88% at baseline;????? but not in the control group. CRP was significantly decreased in the treatment group but no significant change occurred in the control group.

Conclusion: Pentoxifylline is effective in improvement of erythropoietin-resistant anemia in ESRD patients.

Implication for health policy/practice/research/medical education:

Pentoxifylline is effective in improvement of erythropoietin-resistant anemia in ESRD patients.

Please cite this paper as: Shahbazian H, Ghorbani A, Zafar-Mohtashami A, Balali A, AleAli A, Gholam Reza Lashkarara GR. Administration of pentoxifylline to improve anemia of hemodialysis patients. J Renal Inj Prev. 2017;6(1):61-64. DOI: 10.15171/jrip.2017.11.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 1787

Your browser does not support the canvas element.


PDF Downloaded: 907

Your browser does not support the canvas element.